Rekombinanter PDCD1 (Cemiplimab Biosimilar) Antikörper

Produktnummer ABIN7795092

Der Maus Monoklonal anti-PDCD1 (Cemiplimab Biosimilar) Antikörper wird verwendet zum Nachweis von PDCD1 (Cemiplimab Biosimilar) in Proben von Human. Er wurde validiert für FACS und in vivo.

Kurzübersicht für Rekombinanter PDCD1 (Cemiplimab Biosimilar) Antikörper (ABIN7795092)

Target: PDCD1 (Cemiplimab Biosimilar)

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser PDCD1 (Cemiplimab Biosimilar) Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS), In vivo Studies (in vivo)

Güteklasse: Research Grade

Produktdetails anti-PDCD1 (Cemiplimab Biosimilar) Antikörper

Expressionssystem: Mammalian cells

Verwendungszweck: Cemiplimab Biosimilar, PD-1 Monoclonal Antibody

Produktmerkmale: Cemiplimab Biosimilar uses the same protein sequences as the therapeutic antibody cemiplimab. PD-L1 and PD-L2 (B2-DC or CD273, programmed cell death ligand 2) are the two ligands for the receptor PD-1 (CD279, programmed cell death protein 1). Cemiplimab (anti-PD-1) is an intravenous human monoclonal antibody directed against programmed cell death-1 receptor (PD-1) and blocks its interaction with programmed death ligands 1 (PD-L1) and 2 (PD-L2). Cemiplimab blocks T-cell inactivation and enhances the immune system's anti-tumor response. Binding of the programmed death receptor (PD) ligands PD-L1 and PD-L2, to the PD-1 receptor inhibits T-cell proliferation and cytokine production. The upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway may contribute to the inhibition of active T-cell immune surveillance of tumors. Cemiplimab is a recombinant human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2 ligands, causing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In mouse tumor models, blocking PD-1 activity resulted in decreased rates of tumor growth.

Aufreinigung: Protein A or G affinity column

Reinheit: >95 % by reducing SDS-PAGE

Endotoxin-Niveau: < 1 EU per 1 mg of the protein by the LAL method

Immunogen: Human PD1

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: > 3 mg/mL

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Details zu PDCD1 (Cemiplimab Biosimilar)

Target: PDCD1 (Cemiplimab Biosimilar)

Andere Bezeichnung: Cemiplimab Biosimilar

Substanzklasse: Biosimilar